查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153372

全球雙特異性抗體市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Bispecific Antibody Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球雙特異性抗體市場預計將從2025年的185.5億美元成長至2034年的5,114.2億美元，2026年至2034年的複合年成長率（CAGR）將達到44.56%。全球雙特異性抗體市場正經歷快速擴張，主要得益於免疫療法和腫瘤學研究的進步。雙特異性抗體能夠同時結合兩種不同的抗原，從而提供更具標靶性和更有效的治療選擇，尤其是在癌症治療領域。癌症發生率的上升和對精準醫療需求的不斷成長是推動市場成長的主要因素。

對生物技術研發和臨床試驗的大量投資正在加速新型雙特異性抗體候選藥物的開發。製藥公司正與研究機構合作，以提高療效並減少副作用。創新生物製藥的法規核准進一步增強了市場信心，並拓寬了患者的治療選擇。

隨著在研發線產品陸續進入臨床試驗階段，市場前景依然十分光明。除了癌症領域，其他領域的應用，例如自體免疫疾病和感染疾病，也在積極探索中。隨著產能的擴大和抗體工程技術的進步，雙特異性抗體市場預計在未來幾年將迎來顯著成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球雙特異性抗體市場：依適應症分類

  • 市場分析、洞察與預測
  • 癌症
  • 發炎/自體免疫疾病
  • 其他

第5章：全球雙特異性抗體市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第6章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第7章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Roche
    • Amgen
    • AbbVie
    • Johnson & Johnson
    • AstraZeneca
    • Pfizer
    • Sanofi
    • Regeneron
    • Genmab
    • Merck KGaA
    • BeiGene
    • AstraZeneca/Alexion
    • MacroGenics
    • Janssen
    • Numab Therapeutics
    • Zymeworks
    • Harpoon Therapeutics
    • Xencor
    • Merus
    • WuXi Biologics
簡介目錄
Product Code: VMR112112047

The global bispecific antibody market size is expected to reach USD 511.42 Billion in 2034 from USD 18.55 Billion in 2025, growing at a CAGR of 44.56% during 2026-2034.The global bispecific antibody market is witnessing rapid expansion driven by advancements in immunotherapy and oncology research. Bispecific antibodies are designed to bind two different antigens simultaneously, offering targeted and more effective treatment options, particularly in cancer therapy. Rising cancer prevalence and increasing demand for precision medicine are major contributors to market growth.

Significant investments in biotechnology research and clinical trials have accelerated the development of novel bispecific antibody candidates. Pharmaceutical companies are collaborating with research institutions to enhance therapeutic efficacy and reduce side effects. Regulatory approvals of innovative biologics have further strengthened market confidence and expanded treatment options for patients.

Future prospects remain highly positive as pipeline products continue to advance through clinical stages. Applications beyond oncology, including autoimmune and infectious diseases, are being explored. With expanding manufacturing capabilities and technological progress in antibody engineering, the bispecific antibody market is expected to achieve substantial growth in the coming years.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Indication

  • Cancer
  • Inflammatory & Autoimmune Disorder
  • Others

COMPANIES PROFILED

  • Roche, Amgen, AbbVie, Johnson & Johnson, AstraZeneca, Pfizer, Sanofi, Regeneron, Genmab, Merck KGaA, BeiGene, AstraZeneca/Alexion, MacroGenics, Janssen, Numab Therapeutics, Zymeworks, Harpoon Therapeutics, Xencor, Merus, WuXi Biologics

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL BISPECIFIC ANTIBODY MARKET: BY INDICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Indication
  • 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Inflammatory & Autoimmune Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BISPECIFIC ANTIBODY MARKET: BY REGION 2022-2034 (USD MN)

  • 5.1. Regional Outlook
  • 5.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 5.2.1 By Indication
    • 5.2.2 United States
    • 5.2.3 Canada
    • 5.2.4 Mexico
  • 5.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 5.3.1 By Indication
    • 5.3.2 United Kingdom
    • 5.3.3 France
    • 5.3.4 Germany
    • 5.3.5 Italy
    • 5.3.6 Spain
    • 5.3.7 Russia
    • 5.3.8 Rest Of Europe
  • 5.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 5.4.1 By Indication
    • 5.4.2 China
    • 5.4.3 Japan
    • 5.4.4 South Korea
    • 5.4.5 India
    • 5.4.6 Australia
    • 5.4.7 South East Asia
    • 5.4.8 Rest Of Asia Pacific
  • 5.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 5.5.1 By Indication
    • 5.5.2 Brazil
    • 5.5.3 Argentina
    • 5.5.4 Peru
    • 5.5.5 Chile
    • 5.5.6 Rest of Latin America
  • 5.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 5.6.1 By Indication
    • 5.6.2 Saudi Arabia
    • 5.6.3 UAE
    • 5.6.4 Israel
    • 5.6.5 South Africa
    • 5.6.6 Rest of the Middle East And Africa

Chapter 6. COMPETITIVE LANDSCAPE

  • 6.1. Recent Developments
  • 6.2. Company Categorization
  • 6.3. Supply Chain & Channel Partners (based on availability)
  • 6.4. Market Share & Positioning Analysis (based on availability)
  • 6.5. Vendor Landscape (based on availability)
  • 6.6. Strategy Mapping

Chapter 7. COMPANY PROFILES OF GLOBAL BISPECIFIC ANTIBODY INDUSTRY

  • 7.1. Top Companies Market Share Analysis
  • 7.2. Company Profiles
    • 7.2.1 Roche
    • 7.2.2 Amgen
    • 7.2.3 AbbVie
    • 7.2.4 Johnson & Johnson
    • 7.2.5 AstraZeneca
    • 7.2.6 Pfizer
    • 7.2.7 Sanofi
    • 7.2.8 Regeneron
    • 7.2.9 Genmab
    • 7.2.10 Merck KGaA
    • 7.2.11 BeiGene
    • 7.2.12 AstraZeneca/Alexion
    • 7.2.13 MacroGenics
    • 7.2.14 Janssen
    • 7.2.15 Numab Therapeutics
    • 7.2.16 Zymeworks
    • 7.2.17 Harpoon Therapeutics
    • 7.2.18 Xencor
    • 7.2.19 Merus
    • 7.2.20 WuXi Biologics